Reading BMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMY free→Reading BMY? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMY free→QuarterlyIQ Insights · BMY
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(12.4) + peer(0.2*0) + term(0.0) → 4.34% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On April 30, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the first quarter of 2026. A copy of the Earnings Press Release is furnished pursuant to this
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On February 5, 2026, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the fourth quarter of 2025 and full year of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 30, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the third quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 31, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) on its website at www.bms.com announcing its financial results for the second quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On April 24, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2025. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On February 6, 2025, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2024 and full year of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 31, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 26, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On April 25, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2024. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On February 2, 2024, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2023 and full year of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 26, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 27, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On April 27, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the first quarter of 2023. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On February 2, 2023, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the fourth quarter of 2022 and full year of 2022. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On October 25, 2022, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the third quarter of 2022. A copy of the Earnings Press Release is furnished pursuant to this
Results of Operations and Financial Condition. On July 27, 2022, Bristol-Myers Squibb Company (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the second quarter of 2022. A copy of the Earnings Press Release is furnished pursuant to this